Antiemetics and Antinauseants Market Report 2025

The antiemetics and antinauseants market size has grown steadily in recent years. It will grow from $8.11 billion in 2024 to $8.45 billion in 2025 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to historical branding and market competition, historical treatment preferences, economic conditions, historical global health events, medical advancements and research.

The antiemetics and antinauseants market size is expected to see steady growth in the next few years. It will grow to $9.7 billion in 2029 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to research and development initiatives, economic factors, market competition and industry trends, changing disease patterns, healthcare policies and regulations. Major trends in the forecast period include increased focus on patient experience, changing healthcare policies, consumer preference for non-invasive treatments, rising prevalence of chemotherapy and pregnancy-related nausea, emergence of targeted therapies.

The antiemetics and antinauseants market is propelled by the rising prevalence of cancer. Chemotherapy is one of the most commonly recommended treatments for cancer, and chemotherapy-induced nausea and vomiting (CINV) are among its side effects. Antiemetics can help prevent CINV in approximately 60%-70% of patients. For instance, in April 2024, the American Cancer Society, a non-profit organization based in the United States, projected around 609,000 cancer-related deaths and anticipated 1.9 million new cancer cases identified in the country in 2022. An estimated 620,000 cancer deaths are expected, indicating a slight increase in mortality rates for 2024. As the incidence of cancer rises, the demand for antiemetics and antinauseants will increase, thereby boosting market revenue.

The growing prevalence of tuberculosis is anticipated to drive the expansion of the antiemetics and antinauseants market. Tuberculosis (TB) is an infectious bacterial disease that primarily affects the lungs. Antiemetics and antinauseants are used to manage nausea and vomiting caused by anti-tuberculosis medications. For instance, in November 2023, the Global Tuberculosis Report 2023 published by the World Health Organization, a Switzerland-based intergovernmental organization, stated that approximately 10.6 million individuals (with a 95% uncertainty interval of 9.9 to 11.4 million) contracted tuberculosis globally in 2022, up from 10.3 million cases in 2021. Thus, the increased prevalence of tuberculosis is expected to drive growth in the antiemetics and antinauseants market.

Major companies in the antiemetic and antinauseant markets are focusing on new product innovations, such as ready-to-use injectables, to simplify treatment processes and improve patient compliance. These ready-to-use formulations are designed for immediate effectiveness, minimizing the time and complexity associated with traditional injectable medications. For example, in July 2024, Amneal Pharmaceuticals, a US-based specialty pharmaceutical company, introduced FOCINVEZ, the first ready-to-use injectable formulation of fosaprepitant aimed at preventing acute and delayed nausea and vomiting related to highly emetogenic cancer chemotherapy. This product comes in a 150 mg/50 mL vial, is free of Polysorbate 80, and requires no reconstitution or dilution, enabling direct administration. FOCINVEZ is approved for use in adults and pediatric patients aged six months and older and has received a unique J-Code (J1434) for reimbursement.

Government agencies such as the US Food and Drug Administration (FDA) regulate the antiemetics and antinauseants market. In the USA, specific regulations outlined in title 21 of the FDA's Department of Health and Human Services govern the conditions that antiemetic and antinauseant drugs must fulfill to remain in the market, covering definitions, regulations, and labeling requirements.

Major companies in the antiemetic and antinauseant markets are focusing on new product innovations, such as metal-free nasal spray pumps, to address customer needs in the market. A metal-free nasal spray pump is a dispensing device designed without metal components, ensuring compatibility with sensitive formulations like saline solutions or pharmaceutical sprays. For example, in January 2023, Aptar Pharma, a US-based company that specializes in designing and manufacturing drug delivery systems, introduced the APF Futurity nasal spray pump to meet the growing demand for sustainable, recyclable pharmaceutical packaging. With a metal-free design for easier recycling, the APF Futurity has achieved Class A recyclability certification in European streams. Its user-friendly design allows for disposal as a single unit, while advanced dosing technology ensures accurate delivery. This innovative pump integrates Aptar's Advanced Preservative-Free (APF) technology with improved recyclability, providing a sustainable yet high-performance packaging solution.

Major companies operating in the antiemetics and antinauseants market include Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Cipla Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Kyowa Hakko Kirin Pharma Co. Ltd., Daiichi Sankyo Company, Braun GmbH, Eisai Co. Ltd., Sun Pharmaceuticals Industries Ltd., Dr. Reddy's Laboratories, Hikma Pharmaceuticals plc, IPCA Laboratories Ltd., Eagle Pharmaceuticals Inc., Cadila Pharmaceuticals Ltd., Bristol Laboratories Ltd., Tesaro Inc., SRS Pharmaceuticals Pvt. Ltd., Acacia Pharma Ltd., Algen Healthcare Ltd., Mirabilia Sciences Pvt. Ltd., Helsinn Healthcare SA.

North America was the largest region in the antiemetics and antinauseants market in 2024. The Middle East is expected to be the fastest-growing region in the global antiemetics and antinauseants market share. The regions covered in the antiemetics and antinauseants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antiemetics and antinauseants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Antiemetics and antinauseants are medications employed in the prevention or management of vomiting resulting from emetogenic chemotherapy and for addressing postoperative nausea and vomiting. These drugs are effective in preventing, controlling, or treating nausea and vomiting triggered by various factors, including other medications, motion sickness, infections, stomach flu, or chemotherapy. Their mechanism of action involves blocking signal messages to the brain's nausea and vomiting control center, thus alleviating the symptoms.

The primary categories of drugs within the realm of antiemetics and antinauseants encompass dopamine antagonists, NK1 receptor antagonists, antihistamines (H1 histamine receptor antagonists), cannabinoids, benzodiazepines, anticholinergics, steroids, 5-HT3 receptor antagonists, and others. Dopamine antagonists, also known as anti-dopaminergics or dopamine receptor antagonists, function by blocking dopamine receptors and find applications in chemotherapy, motion sickness, gastroenteritis, general anesthetics, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, and various other contexts. These medications are utilized in diverse healthcare settings, including hospitals, medical centers, clinics, and research institutes.

The antiemetics and antinauseants market research report are one of a series of new reports that provides antiemetics and antinauseants market statistics, including antiemetics and antinauseants industry global market size, regional shares, competitors with antiemetics and antinauseants market share, detailed antiemetics and antinauseants market segments, market trends and opportunities, and any further data you may need to thrive in the antiemetics and antinauseants industry. This antiemetics and antinauseants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antiemetics and antinauseants market consists of sales of dopamine, serotonin, neurokinin, histamine, and acetylcholine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.